摘要
目的 探讨马来酸阿伐曲泊帕治疗肝硬化合并血小板减少症(thrombocytopenia,TCP)患者的临床疗效。方法 选取2022年1—12月首都医科大学附属北京佑安医院肝硬化伴重度TCP(PLT<50×10~9/L)患者151例,患者均接受马来酸阿伐曲泊帕治疗,检测患者治疗后30 d内PLT。根据治疗后30 d内PLT结果分为PLT达标组(n=117,PLT≥50×10~9/L)和未达标组(n=34,PLT <50×10~9/L),采用多因素logistic回归方程分析马来酸阿伐曲泊帕治疗肝硬化合并TCP患者PLT达标率的影响因素。结果 151例患者中男112例(74.2%)、女39例(25.8%),平均年龄(57.2±19.3)岁,PLT达标率为77.5%。多因素回归分析结果显示,年龄≥60岁(OR=3.432,95%CI:1.464~8.044)、肝功能Child-Pugh分级C级(OR=9.416,95%CI:2.416~36.695)的患者,应用马来酸阿伐曲泊帕治疗后的PLT达标率较低。达标组23例患者治疗后的PLT增长曲线结果显示,17例(73.9%)患者的PLT在治疗第15天内达峰值。结论 马来酸阿伐曲泊帕治疗肝硬化TCP的临床疗效较好。高龄、肝功能差是马来酸阿伐曲泊帕治疗肝硬化合并TCP患者PLT达标率的危险因素。
Objective To explore the clinical efficacy of avatrombopag maleate in the treatment of patients with cirrhosis complicated with thrombocytopenia(TCP).Methods A total of 151 patients with cirrhosis complicated with TCP(PLT < 50×10~9/L) from Beijing Youan Hospital affiliated to Capital Medical University from January to December 2022 were selected,and were treated with avatrombopag maleate for 5 d,the PLT was detected within 30 d after treatment.The patients were divided into qualified group(n = 117,PLT ≥ 50 × 10~9/L) and non-qualified group(n = 34,PLT < 50 × 10~9/L) according to the PLT results within 30 d of treatment.Multivariate logistic regression equation was used to analyze the influencing factors of qualified rate of PLT in patients with liver cirrhosis complicated with TCP treated with avatrombopag maleate.Results Among the 151 patients,there were 112 males(74.2%) and 39 females(25.8%),with an average age of(57.2 ±19.3) years.The qualified rate of PLT was 77.5%.Multivariate logistic regression analysis results showed that patients aged ≥60 years(OR = 3.432,95%CI:1.464-8.044),with poor liver function(Child-Pugh grade C)(OR = 9.416,95%CI:2.416-36.695) were more likey to have a lower qualified rate pf PLT.The PLT growth curve of 23 patients in the qualified group showed that 17 patients(73.9%) reached the peak within 15th day of treatment.Conclusions The avatrombopag maleate has a good clinical effect on TCP in patients with liver cirrhosis.Senior age and poor liver function are the risk factors of lower qualified rate of PLT in patients with liver cirrhosis complicated with TCP treated with avatrombopag maleate.
作者
武永乐
易银
张金赫
张世斌
李鹏
丁惠国
董培玲
Wu Yongle;Yi Yin;Zhang Jinhe;Zhang Shibin;Li Peng;Ding Huiguo;Dong Peiling(Digestion Center,Beijing Youan Hospital,Capital Medical University,Beijing 100069,China)
出处
《北京医学》
CAS
2024年第1期1-4,共4页
Beijing Medical Journal
基金
国家自然科学基金(82300596)
首都医科大学附属北京佑安医院中青年人才孵育项目(YNKTQN2021005)。
